Home

About Us

Pharma-Free CME

Resources by Topic

Resources by Type

Teaching Tools

Drug Industry

Contact Us

RSS NEWS FEED

About Us

PharmedOut is an independent project run by physicians for physicians and other prescribers. Our goals are to:

Document and disseminate information about how pharmaceutical companies influence prescribing

Provide access to unbiased information about drugs

Encourage physicians to choose pharma-free CME

PharmedOut is led by a team of physicians and academics and is contributed to by a diverse group. The Principal Investigator is Adriane Fugh-Berman MD and the Project Manager is Alicia M. Bell MS. Contact PharmedOut

What We Do

We provide lectures at Grand Rounds, meetings, conferences, and medical student events. Invite PharmedOut to speak

We provide access to free, web-based, pharma-free CME – enough for any physician in the U.S to fulfill annual CME requirements without taking industry-funded courses.

PharmedOut CME Modules:

Drug Approval in the U.S. (1.0 CME credit)

Generic Drugs: Prescribing Sensibly (1.0 CME credit)

Links to more than 200 more credits of web-based, free, pharma-free CME

We provide news, information, and resources, including our own slideshows, videos, and other audio-visual material, reading recommendations, resources for unbiased drug information, factsheets, and tools for teaching--including the popular Drug Ad Bingo.

PharmedOut slideshows are open access and available for anyone to see, download, or use (we only ask that you credit us.) How to use our materials

Patient factsheets are available: Fast Facts on Generic Drugs

Our PharmedOut videos provide illuminating glimpses behind the scenes through interviews with former and current industry insiders. Transcripts are available too.

Our news section provides a mix of mainstream and not-so-mainstream news. Subscribe to our RSS feed. Read our PharmedOut publications and media mentions.

How You Can Help

PharmedOut is funded through the Attorney General Consumer and Prescriber Education grant program, created as part of a 2004 settlement between Warner-Lambert, a division of Pfizer, Inc., and the Attorneys General of 50 States and the District of Columbia, to settle allegations that Warner-Lambert conducted an unlawful marketing campaign for the drug Neurontin® (gabapentin) that violated state consumer protection laws.

---

Who We Are

Adriane Fugh-Berman, MD

Principal Investigator
Contact Dr. Fugh-Berman


Alicia M. Bell, MS

Project Manager
Contact Ms. Bell

---

Our Videos



Pharma Insider II
Opposition research
(read transcript)

---

Pharma Insider I
Off-label promotion under the radar
(read transcript)

---

The Art of Medical Writing
Pharma's anonymous writers

---

Drug Reps Talk Shop II
Drug reps continue their chat

---

Drug Reps Talk Shop I Selling drugs to docs

---

Director of PharmedOut Explains the Project

---

Zyprexa Drug Rep Tells All Shahram Ahari describes how he sold the drug

---

News

Vermont Acts to Make Drug Makers’ Gifts Public
Free meals banned NYT

---

Physician Found Money, Acclaim Seductive
Former thought leader repents Journal Sentinel

---

Doctor Falsified Study on Injured GIs
Infuse success rate questioned NYT (read update)

---

Top 15 Big Pharma Paychecks of 2008
J&J CEO tops list at $29.4M Fierce Pharma

---

29 Percent of Cancer Studies Report Conflict of Interest
Industry funding common Science Daily (read press release; read study abstract)

---

Merck Paid for Medical ‘Journal’
Elsevier Published 6 Fake Journals NYT (read The Scientist)

---

The Next Phase in Industry-Funded Medical Education
“Product theater” at APA meeting Carlat Psych Blog (read more)

---

A Celebrity Patient's Backing Turns Sour for Drug Company
Controversy surrounds Abilify WSJ (read commentary)

---

IOM Says New Rules Needed
Limiting drug company influence over doctors AP (read report)

---

Commentary

New Drugs Have Allure, Not Track Record
Older drugs can be more effective NYT (read more)

---

Swine Flu
Who will bring home the bacon? Unsilent Generation

---

JAMA COI Controversy Continued
Study protocol changed after NIH approved BMJ Rapid Response

---

Click HERE to read the entire news archives